CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Wedbush Adjusts Price Target on Viridian Therapeutics to $31 From $37, Maintains Outperform Rating

Negative
AI Analysis

Summary

Wedbush reduced its price target on Viridian Therapeutics from $37 to $31 while maintaining an Outperform rating.

Importance:2/10
Sentiment:
-0.30
price_target_changeanalyst_ratingequity_research
Related Companies

Read the original article

Published by yahoo_finance on April 7, 2026 1:58 PM

Read Original